Friday, November 13, 2026||
MultiKhabarMultiKhabar

Why Hong Kong is losing ground in AI data centre race as Malaysia, Singapore advance

SC
SCMP - China Feed 2
By Leopold Chen
Share:WhatsAppFacebookX (Twitter)Telegram
Why Hong Kong is losing ground in AI data centre race as Malaysia, Singapore advance
Photo / Coverage: SCMP - China Feed 2Credit: Leopold Chen
EXECUTIVE SUMMARY

From large factory premises in Tseung Kwan O to compact, multilayered industrial buildings in Kwai Chung, data centres are spreading into every corner of Hong Kong. The outlook once appeared promising. Property consultancy Cushman & Wakefield ranked the city the fourth-best data centre market globally in 2023, while the government had branded Hong Kong a “prime location for data centres”. But reality has been less kind. Hong Kong was not even among the top 10 Asia-Pacific markets in the...

Key Takeaways

  • Why Hong Kong is losing ground in AI data centre race as Malaysia, Singapore advance.
  • From large factory premises in Tseung Kwan O to compact, multilayered industrial buildings in Kwai Chung, data centres are spreading into every corner of Hong Kong.
  • The outlook once appeared promising.

From large factory premises in Tseung Kwan O to compact, multilayered industrial buildings in Kwai Chung, data centres are spreading into every corner of Hong Kong. The outlook once appeared promising. Property consultancy Cushman & Wakefield ranked the city the fourth-best data centre market globally in 2023, while the government had branded Hong Kong a “prime location for data centres”. But reality has been less kind. Hong Kong was not even among the top 10 Asia-Pacific markets in the...

Share:WhatsAppFacebookX (Twitter)Telegram

Read Complete Original Article

Published originally on SCMP - China Feed 2

Visit Publisher Site →

Related News

🇨🇳 China
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China26m ago

Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists are synthetic...

SCMP - Feed 91
Multikhabar App

All Information In One Place

Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!

Get it on Google Play